The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain

The cannabinoid CB1 receptor is one of the most abundant G protein-coupled receptors in the brain and is a promising target of therapeutic drug development. Success of drug development for neuropsychiatric indications is significantly enhanced with the ability to directly measure spatial and temporal binding of compounds to receptors in central compartments. We assessed the utility of a new positron emission tomography (PET) radioligand to image CB1 receptors in monkey brain. [11C]MePPEP ((3R,5R)-5-(3-methoxy-phenyl)-3-((R)-1-phenyl-ethylamino)-1-(4-trifluoromethyl-phenyl)-pyrrolidin-2-one) has high CB1 affinity (Kb=0.574±0.207 nM) but also moderately high lipophilicity (measured LogD7.4=4.8). After intravenous injection of [11C]MePPEP, brain activity reached high levels of almost 600% standardized uptake value (SUV) within 10–20 min. The regional uptake was consistent with the distribution of CB1 receptors, with high radioactivity in striatum and cerebellum and low in thalamus and pons. Injection of pharmacological doses of CB1-selective agents confirmed that the tracer doses of [11C]MePPEP reversibly labeled CB1 receptors. Preblockade or displacement with two CB1 selective agents (ISPB; (4-(3-cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide) and rimonabant) showed that the majority (>89%) of brain uptake in regions with high receptor densities was specific and reversibly bound to CB1 receptors in the high binding regions. [11C]MePPEP was rapidly removed from arterial plasma. Regional brain uptake could be quantified as distribution volume relative to the concentration of parent radiotracer in plasma. The P-glycoprotein (P-gp) inhibitor DCPQ ((R)-4-[(1a,6,10b)-1,1-dichloro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]-[(5-quinolinyloxy)methyl]-1-piperazineethanol) did not significantly increase brain uptake of [11C]MePPEP, suggesting it is not a substrate for this efflux transporter at the blood–brain barrier. [11C]MePPEP is a radioligand with high brain uptake, high specific signal to CB1 receptors, and adequately fast washout from brain that allows quantification with 11C (half-life=20 min). These promising results in monkey justify studying this radioligand in human subjects.

[1]  T. Vanderah,et al.  The Cannabinoid Agonist WIN55,212-2 Suppresses Opioid-induced Emesis in Ferrets , 2001, Anesthesiology.

[2]  R. Dannals,et al.  Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. , 2000, Nuclear medicine and biology.

[3]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Herbert,et al.  Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. , 2002, Nuclear medicine and biology.

[5]  Dean F. Wong,et al.  11 C-JHU 75528 : A Radiotracer for PET Imaging of CB 1 Cannabinoid Receptors , 2006 .

[6]  M. Minchin,et al.  Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.

[7]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[8]  M. Shen,et al.  The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons , 1998, Brain Research.

[9]  A. Wolf,et al.  PET studies in the primate brain and biodistribution in mice using (−)-5′-18 F-Δ 8-THC , 1991, Pharmacology Biochemistry and Behavior.

[10]  N. Volkow,et al.  In vivo imaging of the brain cannabinoid receptor. , 2002, Chemistry and physics of lipids.

[11]  N. Volkow,et al.  Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 , 2000, Synapse.

[12]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[13]  Christopher P Cannon,et al.  Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors , 2006, Expert opinion on investigational drugs.

[14]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[15]  Makoto Inoue,et al.  Template-Based Method for Multiple Volumes of Interest of Human Brain PET Images , 2002, NeuroImage.

[16]  D. McClure,et al.  Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[17]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: I. Kinetic Modeling of Single Bolus Experiments , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  M. Phelps,et al.  Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PET , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Arman Rahmim,et al.  11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  T. Reader,et al.  Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity. , 1989, The Journal of pharmacology and experimental therapeutics.

[21]  A. Hoffman,et al.  Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.

[22]  David G. Lambert,et al.  Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist , 1996, Neuroscience Letters.

[23]  D. Osei-Hyiaman,et al.  Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.

[24]  A. Hohmann,et al.  The neurobiology of cannabinoid analgesia. , 1999, Life sciences.

[25]  T. Kirkham,et al.  Endocannabinoids in appetite control and the treatment of obesity. , 2006, CNS & neurological disorders drug targets.

[26]  H. Akaike A new look at the statistical model identification , 1974 .

[27]  John H. Krystal,et al.  Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .

[28]  D. Horrobin,et al.  Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[29]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[30]  John Cawley,et al.  The determination of , 1993 .

[31]  P. R. Bevington,et al.  Data Reduction and Error Analysis for the Physical Sciences , 1969 .

[32]  S. Goldberg,et al.  Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence , 2005, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Wolf,et al.  PET studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta 8-THC. , 1991, Pharmacology, biochemistry, and behavior.

[34]  Jeih-San Liow,et al.  PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  C. Halldin,et al.  Saturation of striatal D(2) dopamine receptors by clozapine. , 2002, The international journal of neuropsychopharmacology.

[36]  N. Volkow,et al.  123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. , 1996, European journal of pharmacology.

[37]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[38]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[39]  F. Yasuno,et al.  Quantification of serotonin 5‐HT1A receptors in monkey brain with [11C](R)‐(−)‐RWAY , 2006, Synapse.